Lithium Discontinuation Against Its Own Rebound Mania Risk
A single patient, twelve years stable on lithium, now facing acute kidney injury that requires stopping it immediately — the one mood stabilizer whose abrupt discontinuation carries its own distinct, time-concentrated relapse risk.
P.S. is a 58-year-old man who has been raising his two teenage grandchildren alone for the past three years. He has bipolar I disorder, stable on lithium for the past twelve years with no manic episodes since starting it. He came to his primary care doctor last week for fatigue and noticeably less urination than usual, and bloodwork showed his creatinine had climbed from a baseline of 0.9 to 2.1 over the past month — acute kidney injury, in a patient whose kidneys had been unremarkable on every prior lithium monitoring panel. Nephrology's recommendation is unambiguous from their side: stop the lithium now, because continuing a nephrotoxic drug through active kidney injury risks converting a reversible insult into permanent chronic kidney disease.
The psychiatric side of this is not simply a matter of yielding to that recommendation, because abrupt lithium discontinuation carries a specific, sharper risk than stopping most other mood stabilizers: rebound mania, a well-documented phenomenon distinct from the general elevated relapse risk seen after stopping any maintenance medication, concentrated heavily in the first few weeks after the drug is stopped and substantially reduced by tapering gradually rather than stopping all at once. But a gradual taper is not medically available to him here — his kidneys are actively injured right now, and continuing any dose of lithium while that injury is ongoing is itself the risk nephrology is trying to stop. The two specialties are not disagreeing about the facts; they are both responding correctly to a real risk that happens to point toward opposite management on the same drug, on the same patient, this week.
Reconciling two urgent, opposing recommendations
His creatinine more than doubled in a month with no other identified cause, and lithium nephrotoxicity in that setting can progress from reversible to permanent surprisingly quickly. I can't recommend continuing any dose while this injury is active — the taper timeline psychiatry would prefer isn't available to us medically right now.
I'm not disputing the nephrology recommendation — I agree lithium has to stop now. What I want on record is that stopping it abruptly, without anything else in place, leaves him with a rebound mania risk that is real and time-concentrated, not a vague long-term possibility. The answer isn't slowing the lithium taper, it's starting a replacement mood stabilizer concurrently rather than sequentially.
Valproate is renally eliminated to a much smaller degree than lithium and can be started at the same visit lithium is stopped — that's the piece that actually solves this, not a taper we don't have time for.
Agreed, and I'd add the practical stakes explicitly: he is the only caregiver for two teenagers right now. An untreated rebound manic episode in the next few weeks isn't just a psychiatric setback for him, it's a household with no functioning adult in it. That argues for close follow-up contact in the first two weeks specifically, not just a prescription and a routine follow-up date.
Lithium stopped immediately and divalproex sodium ER started the same day at 500mg twice daily, rather than tapering lithium on any delay. Nephrology follow-up scheduled at one week to track renal recovery, and psychiatry follow-up scheduled at both one week and two weeks specifically to screen for early rebound manic symptoms during the highest-risk window.
Both specialties agreed on the plan, but the underlying tension was not eliminated, only managed: starting valproate the same day reduces rebound risk, it does not remove it, and everyone involved was explicit that his family situation raises the real-world stakes of a relapse in the next few weeks well above what the lab values alone would suggest.